Medpace Holdings Inc
NASDAQ:MEDP

Watchlist Manager
Medpace Holdings Inc Logo
Medpace Holdings Inc
NASDAQ:MEDP
Watchlist
Price: 560.22 USD 0.42% Market Closed
Market Cap: 15.8B USD

Intrinsic Value

The intrinsic value of one MEDP stock under the Base Case scenario is 380.41 USD. Compared to the current market price of 560.22 USD, Medpace Holdings Inc is Overvalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MEDP Intrinsic Value
380.41 USD
Overvaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Medpace Holdings Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about MEDP?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is MEDP valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Medpace Holdings Inc.

Explain Valuation
Compare MEDP to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Medpace’s heavy reliance on smaller biotech and emerging pharma clients could backfire if funding conditions tighten, as these customers often struggle to secure sustained capital for drug development, directly impacting Medpace’s project pipeline and revenue growth.

Compared to major CRO peers that offer broader therapeutic coverage and global footprints, Medpace could see stalled contract wins or more pricing pressure, given its narrower focus and smaller scale in an increasingly consolidated industry.

Medpace’s aggressive expansion into new service offerings risks operational inefficiencies and elevated overhead if integration costs outstrip near-term project revenue, pressuring profitability and straining its balance sheet.

Bull Theses

Medpace’s niche expertise in full-service clinical trial management for small to mid-sized biotech firms positions it to capture growing demand for specialized drug development support, particularly in oncology and rare diseases where innovation is robust.

Its high-touch, integrated service model fosters close client relationships and repeat business, allowing Medpace to differentiate effectively from larger competitors that often struggle to provide the same level of customization and attention.

Strong operating margins and disciplined cost control underscore Medpace’s ability to generate solid free cash flow, which supports reinvestment in new service capabilities and potential strategic acquisitions that further broaden its offerings.

Show More Less
How do you feel about MEDP?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Medpace Holdings Inc

Current Assets 737.3m
Cash & Short-Term Investments 285.4m
Receivables 373m
Other Current Assets 78.9m
Non-Current Assets 1B
PP&E 256.8m
Intangibles 696.1m
Other Non-Current Assets 62.9m
Current Liabilities 1.3B
Accounts Payable 26.5m
Accrued Liabilities 393.7m
Other Current Liabilities 863.7m
Non-Current Liabilities 175.5m
Other Non-Current Liabilities 175.5m
Efficiency

Free Cash Flow Analysis
Medpace Holdings Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Medpace Holdings Inc

Revenue
2.4B USD
Cost of Revenue
-1.6B USD
Gross Profit
733.6m USD
Operating Expenses
-226.6m USD
Operating Income
507m USD
Other Expenses
-74m USD
Net Income
433m USD
Fundamental Scores

MEDP Profitability Score
Profitability Due Diligence

Medpace Holdings Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
Exceptional ROE
Positive 3Y Average ROIC
Exceptional ROIC
72/100
Profitability
Score

Medpace Holdings Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

MEDP Solvency Score
Solvency Due Diligence

Medpace Holdings Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
76/100
Solvency
Score

Medpace Holdings Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MEDP Price Targets Summary
Medpace Holdings Inc

Wall Street analysts forecast MEDP stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MEDP is 547.08 USD with a low forecast of 305.23 USD and a high forecast of 687.75 USD.

Lowest
Price Target
305.23 USD
46% Downside
Average
Price Target
547.08 USD
2% Downside
Highest
Price Target
687.75 USD
23% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Medpace Holdings Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for MEDP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

MEDP Insider Trading
Buy and sell transactions by insiders

MEDP News

Other Videos
What is the Intrinsic Value of one MEDP stock?

The intrinsic value of one MEDP stock under the Base Case scenario is 380.41 USD.

Is MEDP stock undervalued or overvalued?

Compared to the current market price of 560.22 USD, Medpace Holdings Inc is Overvalued by 32%.

Back to Top